Congress Speakers

  • Thomas Wilckens, Germany | Congress Chair

    Thomas Wilckens, Germany | Congress Chair

    Dr. Thomas Wilckens is a medical doctor and a serial entrepreneur. He serves as the CEO of InnVentis Ltd., with a focus on the convergence of multi-omics technologies with real-world clinical data and machine learning to enable Precision Medicine. 
  • Marta Alarcón Riquelme, Spain

    Marta Alarcón Riquelme, Spain

    Marta Alarcón Riquelme has a background in Medicine, Immunology and Genetics. For over 20 years of her research career she has focused in the identification of the genetic basis of SLE as a first building block towards understanding how such genes lead to cellular abnormalities that eventually lead to clinical disease.
  • Richard Barker, UK

    Richard Barker, UK

    Richard is an internationally respected leader in healthcare and life sciences. 
    He is Founding Director of New Medicine Partners, a global firm assisting public and private sector organisations to accelerate the development and adoption of precision medicine. 
  • Jan Baumbach, Germany

    Jan Baumbach, Germany

    Jan Baumbach studied Applied Computer Science in the Natural Sciences at Bielefeld University in Germany. His research career started at Rothamsted Research in Harpenden (UK) where he worked on computational methods for the integration of molecular biology data.
  • Alexander Belcredi, Austria

    Alexander Belcredi, Austria

    Alexander Belcredi serves as the CEO of PhagoMed Biopharma GmbH, a company he co-founded in 2017. Before setting up the company, Alexander spent close to 10 years at The Boston Consulting Group (BCG). 
  • Daniel Bock, Germany

    Daniel Bock, Germany

    Dr. Daniel Bock has been in pharmaceutical R&D with a focus on inflammatory diseases for 20 years. His expertise spans from early drug discovery to clinical proof of concept and beyond.
  • Thomas Brenzikofer, Switzerland

    Thomas Brenzikofer, Switzerland

    Thomas Brenzikofer is Director DayOne Initiative and Senior Project Manager ICT. Since January 2017, he has focused on developing the Precision Medicine functional area under the "DayOne" label, and is also the media spokesperson for
  • Catherine Brownstein, USA

    Catherine Brownstein, USA

    Dr. Brownstein is an Instructor in Pediatrics at Harvard Medical School and a Research Associate in the Division of Genetics and Genomics at Boston Children's Hospital. 
  • Thierry Colin, France

    Thierry Colin, France

    After several internships at Argonne National Laboratory in Chicago, Thierry Colin defended his PhD in Paris in Applied Mathematics. He then moved to Bordeaux, where he became a University Professor.
  • Khalid A. Fakhro, Qatar

    Khalid A. Fakhro, Qatar

    Dr Khalid A. Fakhro is Director of the Human Genetics Department at Sidra Medicine – a state-of-the-art pediatric hospital in Doha, Qatar. He received his undergraduate degree in Cell Biology from the University of Chicago and his Ph.D. in Human Genetics from Yale University, where he was part of a Howard Hughes Medical Scholars program studying the molecular underpinnings of human disease “from bench-to-bedside.” 
  • Maria Teresa Ferretti, Switzerland

    Maria Teresa Ferretti, Switzerland

    Maria Teresa is a neuroimmunologist and science advocate with 10-year+ international experience in the field of Alzheimer’s disease. 
    After a master in Pharmaceutical Chemistry in 2005 (University of Cagliari, Italy), she obtained a PhD in Pharmacology and Therapeutics at McGill University (Montreal, Canada) in 2011, following a stage at the Center of Excellence for Drug Discovery of GlaxoSmith&Kline (Harlow, England).
  • Armin Furtwängler, Germany

    Armin Furtwängler, Germany

    Dr. med. Armin Furtwängler is Global Senior Medical Director - Health Care Innovation at Boehringer Ingelheim. His focus areas include New Business Models & Health Care Innovation – not typically associated and expected in a (very) traditional German Pharmaceutical Company.
  • Peter Groenen, Switzerland

    Peter Groenen, Switzerland

    Peter Groenen currently heads the Translational Science Group at Idorsia Pharmaceuticals. Holding a PhD in molecular genetics he is extremely interested in the molecular aspects of disease and treatment. He received is MSc in Biochemistry and Physiology from the Radboud University, Nijmegen the Netherlands.
  • Athula Herath

    Athula Herath

    Athula Herath leads the Real World Evidence Epidemiology group globally within the Real World Evidence function of the Global Medical Affairs of Novartis Pharmaceuticals. 
  • Pierre-Louis Joffrin, UK

    Pierre-Louis Joffrin, UK

    Pierre-Louis Joffrin initially studied Biochemistry followed by a postgraduate in Pharmacology at the University of Oxford with a focus on breast cancer biomarkers. 
  • Dennis Lauth, Germany

    Dennis Lauth, Germany

    Dennis has more than 20 years of industry and strategy consultancy experience and a proven track record in building, developing and transforming high performing organizations. He served as Senior Vice President Strategy and Business Excellence for Takeda Pharmaceuticals. 
  • Michael Liebman, USA

    Michael Liebman, USA

    Michael N. Liebman, Ph.D (theoretical chemistry and protein crystallography) is the Managing Director of IPQ Analytics, LLC and Strategic Medicine, Inc after serving as the Executive Director of the Windber Research Institute (now Chan Soon-Shiong Institute for Molecular Medicine) from 2003-2007.  He is an Adjunct Professor of Pharmacology and Physiology at Drexel College of Medicine and Adjunct Professor of Drug Discovery, First Hospital of Wenzhou Medical University and also Fudan University. 
  • Simon Lucas, Germany

    Simon Lucas, Germany

    Simon Lucas is part of the Technology Foresight & Scouting team of Merck’s New Business Builder organization. In his role as an Innovation Field Explorer he is responsible for identifying, exploring, and developing unprecedented opportunities between and beyond the company’s existing offering. 
  • Alexander Manta, Germany

    Alexander Manta, Germany

    Alexander, who has a degree in Cybernetics and Statistics and a PhD in Reliability Engineering, has 25 years of experience in establishing and running data processing and data analysis groups in pharmaceutical industry, with a strong emphasis on machine learning and AI.
  • Enkelejda Miho, Switzerland

    Enkelejda Miho, Switzerland

    Enkelejda Miho is a Professor at Institute of Medical and Analytical Technologies, School of Life Sciences, FHNW Switzerland. Prof. Miho is interested in personalized medicine and artificial intelligence. 
  • Patrick Pfeffer, Germany

    Patrick Pfeffer, Germany

    Dr. Patrick Pfeffer (born 1980), founder of aescuvest GmbH, responsible for business development and strategic corporate management. He graduated with a degree in bioinformatics and a doctorate in pharmaceutical chemistry. 
  • Achim Plum, Germany

    Achim Plum, Germany

    Dr. Achim Plum is Chief Business Officer of the Curetis Group, a Stuttgart, Germany, based diagnostics company focusing on solutions for molecular microbiology. In this function, he oversees all corporate development, business development and strategic activities.
  • Axel Polack, Germany

    Axel Polack, Germany

    Dr. Axel Polack is a General Partner at the “Joint Polish Investment Fund” (, a life science oriented early stage venture capital fund.
  • Kristina Preuer, Austria

    Kristina Preuer, Austria

    After studying Biological Chemistry at the University of Linz and České Budějovice, Kristina Preuer studied Bioinformatics in Linz.
  • Mark Punyanitya, USA

    Mark Punyanitya, USA

    Mark Punyanitya is a Biomedical Engineer with advanced degrees in Applied Physiology & Applied Clinical Trials.
  • Michael Rebhan, Switzerland

    Michael Rebhan, Switzerland

    After a PhD on the biology of disease (1996, in Germany), Dr. Rebhan did a postdoc in bioinformatics (creating GeneCards, at the Weizmann Institute, Israel, until 1998), and then joined industry as a scientist in AstraZeneca during the early days of omics and ‘big data’ technology (Boston, USA).
  • John Ryals, USA

    John Ryals, USA

    Dr. John Ryals co-founded Metabolon, Inc. in 2002 and serves as Founder, Board Member and Chairman Emeritus having recently stepped down as President and CEO in May, 2018 after 16 years. Metabolon is a pioneer and leader in the field of metabolomics and its use in precision medicine and human health. Prior to Metabolon, he was a co-founder, CEO and president of Paradigm Genetics, Inc., a publicly traded agricultural biotechnology company focused on industrializing the process of gene function discovery. 
  • Nicolas Schauer, Germany

    Nicolas Schauer, Germany

    Dr. Nicolas Schauer is the Managing Director of Metabolon’s Potsdam, Germany facility. Prior to joining Metabolon, he was founder and CEO of Metabolomic Discoveries GmbH, a leading European metabolomics company, founded in 2009 and acquired by Metabolon in 2017.
  • Harald Schmidt, The Netherlands

    Harald Schmidt, The Netherlands

    With a double degree in Medicine and Pharmacy, Harald Schmidt has a passion for drug discovery and systems medicine, i.e. using big data, innovative target validation and rapid repurposing of registered drugs for new clinical applications.
  • Ajit Singh, USA

    Ajit Singh, USA

    Ajit Singh focuses on early-stage Technology and Life Science investments. He currently represents Artiman on the Boards of Aditazz, CardioDx, Click Diagnostics, CORE Diagnostics and medECUBE.
  • Dekel Taliaz, Israel

    Dekel Taliaz, Israel

    Dr. Dekel Taliaz is an experienced business manager and experimental neuroscientist. He is currently the CEO and Co-founder of Taliaz Ltd., a personalized medicine startup that has developed Predictix, a game-changing Artificial Intelligence algorithm to help clinicians find the right treatment for each of their patients sooner.
  • Krishnaveni Vijayanand, Germany

    Krishnaveni Vijayanand, Germany

    Krish comes from an engineering background. She has worked for companies like Boeing Company and Schneider Electric. She has completed M.Sc. Business Development from Grenoble Ecole de Management. 

  • Christof Wascher, Switzerland

    Christof Wascher, Switzerland

    Christof Wascher, M.Sc., MBA is Sr. Global Business Manager Life Sciences at Microsoft. He has a background in Engineering, Science and General Management. An experienced, digital and people leader, with unique blend of Pharma Industry experience in commercial and technical roles, at the intersection between IT and business.
  • Justus Wolff, Germany

    Justus Wolff, Germany

    Justus is Manager for Strategy and M&A at Syte - Strategy Advisory for Digital Health.